Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D
Estimated read time 1 min read
Posted in Microsoft

Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D

vm_admin



…

Article Source
https://www.manilatimes.net/2025/03/26/tmt-newswire/globenewswire/bluejay-therapeutics-announces-first-patient-dosed-in-azure-1-global-pivotal-clinical-trial-evaluating-brelovitug-bjt-778-as-a-monotherapy-treatment-for-chronic-hepatitis-d/2080574

You May Also Like

More From Author

SOFTSWISS Deputy CTO Sergey Kastukevich wins EMEA CTO of the Year 2025 at Oracle Excellence Awards | Yogonet International

SOFTSWISS Deputy CTO Sergey Kastukevich wins EMEA CTO of the Year 2025 at Oracle Excellence Awards | Yogonet International

Manufacturing Leaders Bullish on AI for Supply Chain Growth: Study

Manufacturing Leaders Bullish on AI for Supply Chain Growth: Study

Listen to the Podcast Overview

Watch the Keynote